Cefuroxime

Basic Cefuroxime Information

• INN (International Nonproprietary Name): Cefuroxime (Latin: Cefuroximum)
• Brand Names Available In Australia: Zinnat; Zinacef; Ceftin; Elobact; Cefurax; Sharox; Cefuril; Oraxim; region-specific brands (Nivador, Selan, Tilexim, Zinadol, Zipos, Zoref)
• ATC Code: J01DC02 (Second‑generation cephalosporin); ophthalmological code S01AA27 for intracameral use
• Forms & Dosages: Tablets 125 mg, 250 mg, 500 mg; Oral suspension 125 mg/5 mL, 250 mg/5 mL; Powder for injection vials 750 mg, 1.5 g; Eye injection 1 mg/0.1 mL
• Manufacturers In Australia: Global manufacturers include GlaxoSmithKline (Zinnat, Zinacef, Elobact), Apotex and other generics; local availability varies and national registries should be checked for current sponsors
• Registration Status In Australia: Check the TGA ARTG for current registration and approved indications; formulations and sponsors may differ from international markets
• OTC / Rx Classification: Prescription‑only (Rx) in nearly all markets; not available OTC

Critical Warnings & Restrictions (Safety First)

Stop the medicine and seek urgent medical care for any signs of anaphylaxis such as hives, airway tightness or collapse.

Patients with a known allergy to cefuroxime or a history of immediate‑type hypersensitivity to beta‑lactams must not receive cefuroxime.

Pregnancy and lactation are generally considered safe for cefuroxime when clearly indicated, but treatment should be prescribed only after documenting a clear risk–benefit decision.

Severe renal impairment requires dose reduction; for CrCl under 30 mL/min consider halving the dose and involve nephrology or infectious diseases input.

A history of Clostridioides difficile infection or antibiotic‑associated colitis warrants caution before prescribing cefuroxime.

There is no routine age‑based contraindication for elderly patients, but renal function, interactions and fall risk must be assessed.

• Emergency Signs (act immediately) — Hives; Swelling of face/throat; Difficulty breathing; Rapid drop in blood pressure or collapse; New severe rash with blisters.

• Prescriber Checklist — Confirm documented allergy to cefuroxime/cephalosporins and beta‑lactam anaphylaxis history.
• Obtain pregnancy test where relevant and document risk–benefit discussion.
• Check renal function (eGFR/CrCl) and adjust dose as needed.
• Ask about prior C. difficile or antibiotic‑associated colitis.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Cefuroxime can cause dizziness and headache in some patients which may impair driving or operation of machinery.

Advise patients to avoid hazardous tasks until they know how cefuroxime affects them.

Employers and employees should follow workplace safety obligations under Australian law and document any advice given if required.

Q&A — Can I Drive After Taking It In Australia?

Generally you may drive if you feel normal and alert after a dose of cefuroxime.

Do not drive or operate heavy machinery if you experience dizziness, drowsiness or blurred vision while taking cefuroxime.

Check workplace safety obligations and record the counselling advice in the patient file if requested by an employer or for medico‑legal reasons.

Usage Basics

INN, Brand Names Available In Australia

Cefuroxime is the International Nonproprietary Name; Latin form is cefuroximum.

Common global brands listed in registries include Zinnat for oral formulations and Zinacef for injections, though Australian sponsors and stock can differ.

Oral cefuroxime is commonly supplied as the prodrug cefuroxime axetil and IV/IM product as cefuroxime sodium.

Legal Classification (TGA‑Approved, PBS‑Listed)

Cefuroxime is prescription‑only in nearly all markets and is not an over‑the‑counter medicine.

Check the TGA ARTG for current Australian registration details and the PBS schedule for subsidy status, which may be indication‑specific.

• Check TGA ARTG number before supply.
• Verify PBS authority requirements for subsidised prescriptions.
• Confirm prescription type (standard, authority, or private) with the prescriber.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

Adult oral dosing commonly used: 250 mg orally twice daily for many ENT and skin infections.

Higher oral doses of 250–500 mg twice daily are used for lower respiratory tract infections and pneumonia depending on severity.

Early Lyme disease is typically treated with 500 mg orally twice daily for 14–21 days.

Uncomplicated gonorrhoea may be treated with a single 1.5 g IM dose of cefuroxime sodium in some regimens.

For severe infections IV cefuroxime sodium is usually dosed 750 mg–1.5 g every 8 hours, individualised to severity.

Pediatric dosing is generally 10–15 mg/kg twice daily with a usual maximum at the adult dosing level.

• Common Regimens — Tonsillitis/sinusitis: 250 mg PO twice daily × 5–10 days.
• Otitis media/lower RTI: 250–500 mg PO twice daily × 7–10 days.
• Skin/soft tissue: 250–500 mg PO twice daily × 7–10 days.
• Lyme disease: 500 mg PO twice daily × 14–21 days.
• Gonorrhoea: 1.5 g IM single dose.
• Severe systemic infections: IV 750 mg–1.5 g q8h; duration individualised.

Adjustments For Comorbidities

Renal impairment requires dose reduction guided by eGFR or calculated CrCl; severe impairment often needs dose halving or extended dosing intervals.

Hepatic impairment usually does not require dose adjustment unless there is severe liver dysfunction affecting overall metabolism or coagulopathy.

Elderly patients require close monitoring of renal function and electrolytes rather than automatic age‑based dose changes.

Q&A — What If I Miss A Dose?

Take the missed dose as soon as you remember unless the next dose is due soon, in which case skip the missed dose.

Do not double the next dose to make up for a missed dose.

For a single high‑stake dose such as the 1.5 g IM injection for gonorrhoea, contact your prescriber or clinic rather than attempting to replace the dose yourself.

• Patient Checklist — Take missed dose if >4 hours before next scheduled dose.
• Prescriber Checklist — Provide clear instructions for missed doses and document counselling.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Antacids, H2‑blockers and proton pump inhibitors can reduce absorption of oral cefuroxime axetil, so avoid taking these at the same time as the antibiotic.

There is no strong disulfiram‑like interaction reported with cefuroxime, but patients should avoid alcohol while unwell or if experiencing side effects.

Caffeine from coffee does not have a known interaction with cefuroxime.

Common Drug Conflicts

Probenecid increases cefuroxime plasma levels and may prolong its effect.

Concomitant nephrotoxins, for example aminoglycosides, may increase renal risk and require renal monitoring.

Cephalosporins including cefuroxime can rarely affect INR in patients on warfarin or other oral anticoagulants; monitor coagulation if combined.

Live vaccines are not directly contraindicated with antibiotics, but vaccine response may be reduced if taken during an active infection; check immunisation schedules and timing.

• High‑Risk Combos — Probenecid (monitor levels); Aminoglycosides (monitor renal function); Warfarin (monitor INR).
• Alert — Consult a pharmacist or prescriber before starting or stopping interacting medicines.

User Reports & Trends (Australian Perspective)

Australian forum and review feedback commonly notes cefuroxime is effective for ENT and skin infections with good clinical response.

Gastrointestinal side effects such as diarrhoea and nausea are the most frequently reported tolerability issues.

Occasional reports of rash or urticaria appear in consumer comments and should prompt assessment for allergic reaction.

Price sensitivity is common in patient discussions, with preferences for PBS‑subsidised options or generic cefuroxime tablets.

Rural users sometimes report delayed access to injectable formulations and limited stock of specific brands at smaller pharmacies.

• Recurring Positives — Effective for community‑acquired ENT and skin infections; well‑tolerated in many patients.
• Recurring Negatives — GI upset; occasional rash; out‑of‑pocket cost concerns.

• Clinician Checklist For Anecdotes — Note source, date, severity, and seek corroboration from TGA adverse event reports or local pharmacy records.
• Recommendation — Consult the TGA adverse event database and local pharmacy complaint logs for verified safety signals and consider practice audits in GP or rural clinics to collect real‑world outcomes.

Access & Purchase Options

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

Most community pharmacies in Australia can supply oral cefuroxime or order generic equivalents; chain pharmacies often stock common tablet strengths such as 250 mg and 500 mg.

Injectable formulations like Zinacef or generics are typically distributed through hospital pharmacies or larger community pharmacies that hold cold‑chain capacity.

Online Pharmacies And Telehealth E‑Prescriptions

Telehealth e‑prescriptions are commonly accepted by Australian pharmacies and online pharmacies can dispense with courier delivery where permitted.

Patients in remote areas may rely on community nurses, Royal Flying Doctor Service arrangements or hospital outpatient clinics for injectable doses, so planning ahead is important.

In our online pharmacy, cefuroxime is available without a prescription, with discreet delivery to Australia in 9–21 days.

• Patient Checklist For Online Ordering — Verify the pharmacy is authorised and registered, confirm how PBS scripts are handled, and check cold‑chain arrangements for injectable products.

Mechanism & Pharmacology

Simplified Explanation

Cefuroxime is a second‑generation cephalosporin antibacterial that inhibits bacterial cell‑wall synthesis by binding penicillin‑binding proteins, leading to cell lysis.

It has activity against a range of Gram‑positive and certain Gram‑negative organisms and shows stability to some beta‑lactamases.

Clinical Terms

The oral form is commonly cefuroxime axetil, a prodrug requiring absorption, while the IV/IM form is cefuroxime sodium for predictable plasma levels in severe infections.

Peak concentrations, half‑life and tissue penetration vary by route of administration, with IV providing the most reliable plasma exposure for severe disease.

• Definitions — Cefuroxime Axetil: oral prodrug form.
• Cefuroxime Sodium: IV/IM formulation.
• ATC Code: J01DC02 identifies its class as a second‑generation cephalosporin.

Indications & Off‑Label Uses

Approved Indications By TGA (Check ARTG)

Approved uses commonly include tonsillitis, pharyngitis, sinusitis, otitis media, lower respiratory tract infections and skin/soft tissue infections.

Oral cefuroxime is used for early Lyme disease, and injectable cefuroxime is used for more severe infections and for some surgical prophylaxis practices such as intracameral eye use per local protocol.

Uncomplicated gonorrhoea treatment with a 1.5 g IM dose appears in some registries but prescribers should verify current local guidelines and ARTG wording.

Off‑Label Uses In Australian Practice

Clinicians often use cefuroxime as step‑down oral therapy after IV cefuroxime in hospital for susceptible infections.

Occasional targeted therapy for susceptible urinary tract infections and intracameral use during cataract surgery (1 mg/0.1 mL) occurs where local protocols and approvals exist.

Key Clinical Findings

Recent clinical summaries (2022–2026 window) show cefuroxime remains effective for many community‑acquired ENT and skin infections when used appropriately.

Antimicrobial stewardship increasingly emphasises narrow‑spectrum use and timely de‑escalation from broader agents.

Surveillance indicates variable resistance among some Enterobacterales, so local antibiograms should guide empiric prescribing.

IV cefuroxime is a useful agent for step‑down strategies to reduce selection pressure from broader‑spectrum antibiotics.

• Takeaways — Efficacy for common community infections; stewardship importance; check local susceptibility patterns.

• Practice Checklist — Consult local antibiogram; align with NHMRC and hospital guidelines; monitor clinical outcomes.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Pros And Cons Checklist

Pros of cefuroxime include broader Gram‑negative coverage than many oral penicillins and relative stability to some beta‑lactamases.

Cons include potential for gastrointestinal upset, possible cross‑reactivity in penicillin‑allergic patients and access issues for IV formulations in community settings.

• Substitution Checklist — Confirm allergy status, review susceptibility, consider PBS cost and availability before switching.

Common Questions (Pharmacy Consultation FAQs)

Is it safe in pregnancy?

Answer: Generally considered safe when clearly indicated; document the risk–benefit discussion.

Will it treat my sinus infection?

Answer: Cefuroxime is often effective for bacterial sinusitis when a bacterial cause is suspected.

Do I need to finish the course?

Answer: Yes — complete the prescribed course unless severe side effects occur or a clinician advises otherwise.

Can I take it with an antacid?

Answer: Avoid taking antacids at the same time as oral cefuroxime axetil because they may reduce absorption.

• Top FAQs — Include allergy check, symptom review, side‑effect counselling, missed‑dose guidance.

Short Patient Script For Pharmacists: Confirm symptoms and indication; verify allergy to beta‑lactams; explain dosing and duration; warn about GI side effects and severe allergic signs; advise on missed doses and storage.

Document counselling in patient records and report suspected adverse reactions to the TGA.

Price & Access Comparison Table

The template below helps editors populate live pricing; prices vary by region and over time.

• Access Checklist — Check PBS concession eligibility.
• Ask the pharmacist about generic equivalents and confirm injectable arrangements for community administration.
• Consider courier delivery for oral medications and verify stability during transport.

Registration & Regulation

TGA Approval

Always verify current registration and approved indications on the TGA ARTG before prescribing or supplying cefuroxime in Australia.

International trade names such as Zinnat and Zinacef exist, but Australian sponsors and ARTG entries may differ.

PBS Subsidy Details

PBS listings can be indication‑specific and may require authority scripts for some uses; check the PBS Schedule online before prescribing to advise patients on likely costs.

• Definitions — ARTG: Australian Register of Therapeutic Goods.
• PBS: Pharmaceutical Benefits Scheme.
• Authority Script: A PBS requirement for subsidised use in certain indications.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store tablets at 15–25°C in a dry place away from direct sunlight and high humidity.

Reconstituted oral suspension should be refrigerated and discarded after 10 days.

Advise patients in hot or humid regions to keep tablets in their original pack and avoid storing medicines in bathrooms.

Cold‑Chain Handling For Pharmacies

Injection vials should be stored below 25°C and protected from light, with reconstituted solutions used promptly according to the manufacturer.

Pharmacy SOPs should include temperature logs, expiry checks and packing procedures for transit to maintain product integrity.

• Patient Storage Checklist — Keep in original container, out of reach of children, refrigerate suspension and discard after 10 days.
• Pharmacy Procedure — Maintain temperature logs, fridge alarms and documented cold‑chain packing for delivery of injectable products.

Guidelines For Proper Use (Pharmacist Counselling & Patient Advice)

Australian Pharmacist Counselling Style

Confirm the indication and take a focused allergy history including beta‑lactam anaphylaxis before supplying cefuroxime.

Check renal function and concurrent medicines to identify dose adjustments and interactions.

Explain dosing schedule, duration, missed‑dose action and common side effects such as GI upset and rash.

Use plain language, motivational counselling and provide written patient information when possible.

Patient Advice From PBS And National Health Authorities

Advise patients to complete the prescribed course and to avoid unnecessary antibiotic use to protect future effectiveness.

Encourage returning unused antibiotics to a pharmacy for safe disposal.

For immunocompromised or pregnant patients, recommend close liaison with the prescriber and clear documentation in the medical record.

• Provide a short patient checklist handout with dose times, side‑effect signs, storage and disposal instructions.

Delivery Across Australia